New Cloudflare Report Warns of a ‘Technical Glass Ceiling’ Stifling AI Growth and Weakening Cybersecurity January 16, 2026 New research shows that organizations modernizing apps are 3x more likely to see AI payoffs, while those clinging to legacy systems face rising security risks and developer talent shortages
500 Global Announces Promotion of Mei Chel Tan to Global Managing Partner January 16, 2026 Appointment reflects expanding demand for entrepreneurial ecosystem development and AI readiness across emerging markets.
Accertify Appoints CEO and Expands Executive Team to Fuel Next Phase of Growth January 16, 2026 Greg Dukat appointed CEO as Accertify builds leadership depth to accelerate go-to-market execution
Barrows Connected Store Appoints James Hay as Global CEO January 16, 2026 Barrows Connected Store, a global leader in connected retail experiences, today announced the appointment of James Hay as Global Chief Executive Officer, effective January 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114778548/en/ In his new role, Hay will lead the global Barrows Connected Store business, encompassing teams in the UK, [...]
Sixth Street Raises €3.75 Billion for Third European Direct Lending Fund January 16, 2026 Sixth Street SLE III Hits Hard Cap, Reflecting Long-Term Strength as One of Europe’s Leading Private Capital Platforms
WRITER Appoints Mina Alaghband as First Chief Customer Officer to Accelerate Enterprise Transformation with Agentic AI January 16, 2026 Alaghband will lead global customer operations as demand intensifies among Fortune 500 organizations for agentic platforms that accelerate business impact and deliver ROI at scale
Almirall Presents R&D Pipeline Advances Supported by Sustained Growth and Leadership in Medical Dermatology at J.P. Morgan Healthcare Conference January 16, 2026 Pipeline advances in 2026 span a range of dermatology disease areas, including atopic dermatitis, hidradenitis suppurativa, and alopecia areata, with 3 ongoing PoC/Phase II clinical studies* and 3 additional studies to be initiated in 2026. Almirall’s sustained trajectory of growth and profitability enables the company to reach more patients and supports a growth outlook of double-digit net sales through 2030, combined biologics peak sales of approximately €800 MM (Ebglyss® and Ilumetri®), and a 25% EBITDA margin by 2028. Almirall's leadership in medical dermatology, biologics growth, and continued strong performance of its broad product portfolio fuel advancement of a diversified and innovative R&D pipeline addressing skin diseases with high unmet need.
Alpaca Raises $150 Million at a $1.15B Valuation to Build the Global Standard for Brokerage Infrastructure January 16, 2026 Alpaca appoints lead investor Drive Capital’s Co-Founder and Partner Chris Olsen to its board
Capitolis Achieves Record-Breaking 2025 Across Portfolio Optimization Business January 16, 2026 Company delivered record performance across FX, Rates, and Credit products and launched innovative offerings
Paladin EnviroTech Acquires R&L Recycling B.V., Establishing European Platform for ITAD and Sustainable Materials Recovery January 16, 2026 Expansion into Europe Uniquely Positions Paladin to Address Global Hyperscaler Demands